Abstract library

542 results for "radiolabelled somatostatin analogs".
#178 Treatment with 177Lutetium-DOTA-Tyr3-octreotate in Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumors express somatostatin receptors. Treatment with radiolabelled somatostatin analogs has been used for more than 10 years. Useful isotopes are 111Indium, 99Yttrium and 177Lutetium.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Ass Prof Dan Granberg
#2946 Analysis of Factors Related to Gallstones in Patients with Neuroendocrine Tumors Treated with Long-Acting Somatostatin Analogues
Introduction: Somatostatin analogs are the backbone of neuroendocrine neoplasms treatment. Biliary stone disease is a potentially severe adverse event of somatostatin analogs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Zhirong Qi
Authors: Qi Z, Zhang Y, Li Y, Shi Y, ...
#169 Radio guided surgery in neuroendocrine tumours using 68Ga-labeled somatostatin analogs – a pilot study.
Introduction: Radioguided surgery (RGS) is an intraoperative localizing technique for the detection of cancer tissue using tumor-specific radionuclides.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#1774 Report on the Clinicopathological Characteristics of 548 Romanian Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs
Introduction: In Romania, treatment with somatostatin analogs (SSA) for neuroendocrine tumors (NETs) is based on the National Clinical Practice Guideline for the Diagnostic and Treatment of NETs and is reimbursed by the National Health Insurance Company since 2008.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD, PhD, Prof. Fica Simona
#1187 High-Dose Treatment with Somatostatin Analogs in Neuroendocrine Tumors
Introduction: Somatostatin analogs (SSA) effectively control symptoms in neuroendocrine tumours (NET), besides showing antiproliferative activity. In progressive or metastatic NET, increasing SSA dose or shortening the dosing interval are common clinical practice, though empirical.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Roberta Modica
#1529 Somatostatin Receptor PET/CT with Radiolabelled Antagonist Is Twice as Effective as the Agonist for Detecting Liver Metastases: Results of a Phase 1/2 Study Comparing 68Ga-OPS202 with 68Ga-DOTATOC PET/CT in Gastroenteropancreatic NET Patients
Introduction: 68Ga-DOTATOC PET/CT is a reference method for imaging somatostatin receptor (sstr) expressing neuroendocrine tumors (NET). Presence and extent of liver metastases impact on patient management and prognosis.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Guillaume Nicolas
#1756 Somatostatin Analogs in Patients with Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Efficacy and Safety
Introduction: Zollinger-Ellison syndrome (ZES) can cause severe complications. In multiple endocrine neoplasia type 1 (MEN1) related ZES, surgery has a controversial role and proton pump inhibitors (PPI) are usually first-line therapy, although some concerns regarding long-term use. Somatostatin analogs (SSA) both reduce hypergastrinemia and have an antiproliferative role.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Roberta Modica
#2232 Role of Interval Reduction of Somatostatin Analogs in Patients with Progressive Neuroendocrine Tumors: Our Experience
Introduction: Interval reduction of somatostatin analogs (SSAs) is a possibly strategy for elderly patients with progressive metastatic neuroendocrine tumors (NETs). Patients with diagnosis of NET are >75 years old in the 25% of cases. No randomized studies are available to evaluate efficacy of this treatment schedule.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Ivana Puliafito
#2691 Somatostatin Analogs in Patients with Zollinger Ellison Syndrome (ZES): An Observational Study
Introduction: Zollinger Ellison syndrome (ZES) is a rare syndrome caused by gastrin hypersecretion from a primary neuroendocrine tumor (NET), usually located within the duodenum or into the pancreas. Gastrinomas have two important treatment goal: the control of the gastrin-excess state and the control of tumor growth.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: dr Sara Massironi
#3034 Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is ≥ 10%?
Introduction: The antiproliferative effect of first-line long acting somatostatin analogs (SSA) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) was shown in the PROMID and the CLARINET trials. Efficacy data in pancreatic NETs (PanNETs) with Ki-67 ≥ 10% are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD Teresa Alonso Gordoa